Nuclear oxidative damage correlates with poor survival in colorectal cancer

Por Sheridan, J, Wang, L-M, Tosetto, M, Sheahan, K, Hyland, J, Fennelly, D, O'Donoghue, D, Mulcahy, H, O'Sullivan, J
Publicado em 2009

Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive

Por O'Toole, A, Michielsen, A J, Nolan, B, Tosetto, M, Sheahan, K, Mulcahy, H E, Winter, D C, Hyland, J M, O'Connell, P R, Fennelly, D, O'Donoghue, D, O'Sullivan, J, Doherty, G A, Ryan, E J
Publicado em 2014

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

Por Schoemaker, N E, Kuppens, I E L M, Moiseyenko, V, Glimelius, B, Kjaer, M, Starkhammer, H, Richel, D J, Smaaland, R, Bertelsen, K, Poulsen, J P, Voznyi, E, Norum, J, Fennelly, D, Tveit, K M, Garin, A, Gruia, G, Mourier, A, Sibaud, D, Lefebvre, P, Beijnen, J H, Schellens, J H M, ten Bokkel Huinink, W W
Publicado em 2004